Home Cart Sign in  
Chemical Structure| 1418033-25-6 Chemical Structure| 1418033-25-6

Structure of LMK-235
CAS No.: 1418033-25-6

Chemical Structure| 1418033-25-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LMK-235 is a potent and selective HDAC4/5 inhibitor with IC50s of 4.22 nM, 11.9 nM, 55.7 nM, 320 nM, 881 nM, 852 nM, and 1278 nM for HDAC5, HDAC4, HDAC6, HDAC1, HDAC2, HDAC11, and HDAC8, respectively, and is used in cancer research.

Synonyms: LMK-235

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LMK-235

CAS No. :1418033-25-6
Formula : C15H22N2O4
M.W : 294.35
SMILES Code : O=C(NOCCCCCC(NO)=O)C1=CC(C)=CC(C)=C1
Synonyms :
LMK-235
MDL No. :MFCD26522892
InChI Key :VRYZCEONIWEUAV-UHFFFAOYSA-N
Pubchem ID :71520717

Safety of LMK-235

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of LMK-235

epigenetics

Isoform Comparison

Biological Activity

Target
  • HDAC4

    HDAC4, IC50:11.9 nM

  • HDAC5

    HDAC5, IC50:4.2 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
KMT2A-rearranged ALL cell lines 100 nM or 200 nM 96 hours LMK-235 significantly reduced cell viability in KMT2A-rearranged ALL cell lines, leading to apoptosis and G1 cell cycle arrest. PMC11450098
primary KMT2A-rearranged infant ALL patient samples 40-100 nM 96 hours LMK-235 significantly inhibited cell viability in primary KMT2A-rearranged infant ALL patient samples, with IC50 values ranging between 40-100 nM. PMC11450098
A2780 847 nM 72 hours To determine the cytotoxicity of LMK-235 against A2780 cells, with an IC50 value of 847 nM. PMC7663919
A2780CisR 644 nM 72 hours To determine the cytotoxicity of LMK-235 against A2780CisR cells, with an IC50 value of 644 nM. PMC7663919
BON-1 0.02–20 µM 72 h LMK-235 lowered overall cell viability by inducing apoptosis in a dose- and time-dependent manner. PMC6213165
QGP-1 0.02–20 µM 72 h LMK-235 lowered overall cell viability by inducing apoptosis in a dose- and time-dependent manner. PMC6213165
rectal organoids 2.5 μM 24 hours LMK-235 inhibits HDAC4/5 activity, reducing SPINK4 expression under PGE2 stimulation PMC11472582

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice xenograft mouse model of KMT2A-rearranged ALL intraperitoneal injection 100 mg/kg body weight/day once daily for the duration of the study The maximum achievable dose of LMK-235 was insufficient to induce anti-leukemic effects in vivo. PMC11450098

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.40mL

0.68mL

0.34mL

16.99mL

3.40mL

1.70mL

33.97mL

6.79mL

3.40mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories